(Q34311593)

1 August 2017

title

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds (English)

1 reference

cost-effectiveness analysis

1 August 2017

main subject

1 reference

1

Kenneth J Smith

1 reference

1 August 2017

3

Mary Patricia Nowalk

1 reference

1 August 2017

2

Bruce Y Lee

1 reference

1 August 2017

5

Richard K Zimmerman

1 reference

1 August 2017

4

Mahlon Raymund

1 reference

1 August 2017

language of work or name

English

0 references

publication date

29 September 2010

1 reference

1 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

1 August 2017

volume

28

1 reference

1 August 2017

issue

48

1 reference

1 August 2017

page(s)

7620-7625

1 reference

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

A computer simulation of employee vaccination to mitigate an influenza epidemic.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Pneumococcal polysaccharide vaccine: cost-effectiveness recommendations in adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

The timing of influenza vaccination for older adults (65 years and older).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Vaccines for preventing influenza in healthy adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Insights into the interaction between influenza virus and pneumococcus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Pneumococcal vaccine. Efficacy and associated cost savings.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

IOM report: patient safety--achieving a new standard for care.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2981678

What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

28 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.053

Safety of revaccination with pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.053

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.053

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.053

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.053

Immunogenicity of pneumococcal revaccination in patients with chronic disease

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20887828

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.09.053

1 reference

1 August 2017

1 reference

1 August 2017

1 reference